ClinicalTrials.gg
CompletedNCT01129882ASPIREUpdated Jan 6, 2020Results posted

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

A Phase 3 interventional study of Aripiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 157 sites in 24 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-01-06.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
709
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
8th of 125
709 · median 130
Started
2010
with 5 others
Phase 3
34 of 126
1 open now
Registered
63rd of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 8th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2010, is one of 34 in phase 3, and was the 63rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The primary objective of this study was to continue to provide aripiprazole intramuscular (IM) depot treatment (400 milligrams [mg] or 300 mg) to participants with schizophrenia completing the 52-week, open-label safety and tolerability Study 31-08-248. In addition, the secondary objective was to collect additional long-term safety data on aripiprazole IM depot treatment.

Read the detailed description

This was an open-label study that enrolled participants with schizophrenia who had completed the 52-week, open-label safety and tolerability Study 31-08-248 and continued to provide aripiprazole IM depot treatment.

Participants received this treatment until aripiprazole IM Depot was commercially available in any dosage (including generic formulations) in the country where the study was being conducted or the commercial availability of aripiprazole IM Depot was terminated by the sponsor, or until the study completion date of 06 Dec 2018 was reached.

Eligible participants entered this study at the end of treatment visit (Week 52) of Study 31-08-248. Participants continued to receive aripiprazole IM depot every month (study months were every 4 weeks, which were defined as 28 [-2/+10] days) as a continuation of their previous monthly dose in Study 31-08-248.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a current diagnosis of schizophrenia, as defined by , Fourth Edition, Text Revision (DSM-IV-TR) criteria, who completed the open-label extension Study 248 (completed Study 248 study completion visit, Week 52).
  • Participants who, in the investigator's judgment, may benefit from continued participation in an aripiprazole IM Depot study.
  • The baseline visit for Study 270 (which is the Week 52 visit of Study 248) and the first injection for Study 270 must occur within 4 weeks (which was defined as 28 [-2/+10] days) of the last injection in Study 248.
  • Participants who are able to provide written and/or consent obtained from a legally acceptable representative (as required by an Independent Review Board/Independent Ethics Committee (IRB/IEC), prior to the initiation of any protocol-required procedures.
  • Participants able to understand the nature of the study and follow protocol requirements and who can read and understand the written word in order to complete patient-reported outcomes measures.
  • Outpatient status.

Exclusion criteria

Exclusion Criteria:

  • Participants with a current diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic, or other cognitive disorders.
  • Participants with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorder.
  • Participants who currently meet DSM-IV-TR criteria for substance dependence, including alcohol and benzodiazepines, but excluding caffeine and nicotine.
  • Participants with a significant risk of violent behavior or a significant risk of committing suicide based on the investigator's judgment.
  • Participants who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones.
  • Participants with a history of neuroleptic malignant syndrome or tardive dyskinesia at screening.
  • Electroconvulsive therapy within 180 days prior to entry.
  • Any participant who requires or may need any other antipsychotic medications during the course of the study.
  • Aripiprazole IM Depot (including generic formulation) is commercially available in the participant's country.
  • Other protocol specific inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
709 participants (actual)

Study arms

  • Experimental
    Aripiprazole IM depot

    Active treatment of monthly doses of aripiprazole IM depot (300 mg or 400 mg)

    Drug: Aripiprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Number Of Participants Reporting Severe Treatment-Emergent Adverse Events (TEAE)

    A TEAE was defined as an AE that started after start of investigational medicinal product (IMP) treatment or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption, or reduction of IMP. A severe AE was one that caused inability to work or perform normal daily activity. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline to Month 97 (+/- 3 days)

Secondary outcomes

  1. Mean Change In Clinical Global Impression-Severity (CGI-S) of Illness Scale Score From Baseline To Last Visit

    The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The Last Visit was defined as the last available post-baseline evaluation. A decrease in the CGI-S score indicated disease stability or improvement.

    Time frame: Baseline, Month 91

07

Results

Posted Jan 6, 2020

Participant flow

Participant flow — Overall Study
MilestoneAripiprazole IM Depot
Started709
Received at least 1 dose of study drug709
Completed431
Not completed278
Withdrew: Adverse event39
Withdrew: Death6
Withdrew: Lack of efficacy5
Withdrew: Lost to follow-up13
Withdrew: Physician decision27
Withdrew: Protocol deviation3
Withdrew: Withdrawal criteria met19
Withdrew: Trial termination by sponsor6
Withdrew: Withdrawal by subject160

Outcome measures

PrimaryNumber Of Participants Reporting Severe Treatment-Emergent Adverse Events (TEAE)

A TEAE was defined as an AE that started after start of investigational medicinal product (IMP) treatment or if the event was continuous from baseline and was serious, IMP-related, or resulted in death, discontinuation, interruption, or reduction of IMP. A severe AE was one that caused inability to work or perform normal daily activity. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline to Month 97 (+/- 3 days)
Reported as:
Number · participants
Number Of Participants Reporting Severe Treatment-Emergent Adverse Events (TEAE)
participantsAripiprazole IM Depot
Number Of Participants Reporting Severe Treatment-Emergent Adverse Events (TEAE)50
SecondaryMean Change In Clinical Global Impression-Severity (CGI-S) of Illness Scale Score From Baseline To Last Visit

The severity of illness for each participant was rated using the CGI-S scale. To assess CGI-S, the rater or investigator answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" Response choices included: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The Last Visit was defined as the last available post-baseline evaluation. A decrease in the CGI-S score indicated disease stability or improvement.

Time frame:
Baseline, Month 91
Reported as:
Mean · units on a scale
Mean Change In Clinical Global Impression-Severity (CGI-S) of Illness Scale Score From Baseline To Last Visit
units on a scaleAripiprazole IM Depot
Mean Change In Clinical Global Impression-Severity (CGI-S) of Illness Scale Score From Baseline To Last Visit-0.14 ± 0.69

Adverse events

Collected over Baseline to Month 97 (+/- 3 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole IM Depot6/709 (0.8%)62/709 (8.7%)515/709 (72.6%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventAripiprazole IM Depot
SchizophreniaPsychiatric disorders14/709
Psychotic DisorderPsychiatric disorders9/709
PneumoniaInfections and infestations3/709
SeizureNervous system disorders2/709
Suicide AttemptPsychiatric disorders2/709
ThrombocytopeniaBlood and lymphatic system disorders1/709
AnaemiaBlood and lymphatic system disorders1/709
Supraventricular TachycardiaCardiac disorders1/709
Acute Myocardial InfarctionCardiac disorders1/709
Arteriospasm CoronaryCardiac disorders1/709
Most frequent other events
Most frequent other events
EventAripiprazole IM Depot
NasopharyngitisInfections and infestations87/709
Weight IncreasedInvestigations81/709
HeadacheNervous system disorders77/709
InsomniaPsychiatric disorders70/709
Upper Respiratory Tract InfectionInfections and infestations54/709
InfluenzaInfections and infestations48/709
AnxietyPsychiatric disorders44/709
Back PainMusculoskeletal and connective tissue disorders42/709
DiarrhoeaGastrointestinal disorders37/709

Baseline characteristics

All participants who completed week 52 of Study 31-08-248 and enrolled in Study 31-10-270.

Age, Categorical
Age, Categorical(Participants)Aripiprazole IM Depot
<=18 years0
Between 18 and 65 years709
>=65 years0
Age, Continuous
Age, Continuous(Years)Aripiprazole IM Depot
Age (years)41.9 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole IM Depot
Female295
Male414
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aripiprazole IM Depot
White464
Black or African American78
American Indian or Alaska Native1
Asian107
Native Hawaiian or Other Pacific Islander1
Other58
08

Study locations

157 sites
  • Bellevue, California 98007, United States
  • Garden Grove, California 92845, United States
  • Glendale, California 91204, United States
  • Glendale, California 91206, United States
  • Imperial, California 92251, United States
  • Los Angeles, California 90024, United States
  • National City, California 91950, United States
  • National City, California, United States
  • Orange, California 92868, United States
  • Pasadena, California 91107, United States
  • Pico Rivera, California 90660, United States
  • Pico Rivera, California, United States
  • San Bernardino, California 92408-3304, United States
  • San Diego, California, United States
  • Sherman Oaks, California 91403, United States
  • Norwalk, Connecticut 06851, United States
  • Washington, District of Columbia 20016, United States
  • Washington, District of Columbia, United States
  • Bradenton, Florida, United States
  • Doral, Florida, United States
  • Hialeah, Florida 33016, United States
  • Homestead, Florida 33030, United States
  • Orange City, Florida 32763, United States
  • Tampa, Florida 33613, United States
  • Chicago, Illinois 60612, United States
  • Chicago, Illinois 60640, United States
  • Oak Brook, Illinois 60523, United States
  • Indianapolis, Indiana 46222, United States
  • Shreveport, Louisiana 71101, United States
  • Flowood, Mississippi 39232, United States
  • Saint Louis, Missouri 63109, United States
  • North Platte, Nebraska 69101, United States
  • Buffalo, New York 14215, United States
  • New York, New York 10035, United States
  • Queens, New York, United States
  • Rochester, New York 14615, United States
  • Charlotte, North Carolina 28204, United States
  • Akron, Ohio, United States
  • Canton, Ohio 44718, United States
  • Toledo, Ohio 43609, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Allentown, Pennsylvania 18104, United States
  • Jenkintown, Pennsylvania 19046, United States
  • Sellersville, Pennsylvania 18960, United States
  • Charleston, South Carolina 29401, United States
  • Memphis, Tennessee 38119, United States
  • Austin, Texas 78731, United States
  • Austin, Texas 78754, United States
  • DeSoto, Texas 75115, United States
  • Richmond, Virginia 23230, United States
  • Bothell, Washington 98011, United States
  • Milwaukee, Wisconsin 53226, United States
  • Buenos Aires, 1900, Argentina
  • Buenos Aires, C1058AAH, Argentina
  • Buenos Aires, C1405BOA, Argentina
  • Buenos Aires, C1425AHQ, Argentina
  • Mendoza, M5500HYF, Argentina
  • Epping, Victoria 3076, Australia
  • Frankston, Victoria 3199, Australia
  • Fremantle, Western Australia 6959, Australia
  • Bourgas, 8000, Bulgaria
  • Lovech, 5500, Bulgaria
  • Pazardzhik, 4400, Bulgaria
  • Pleven, 5800, Bulgaria
  • Plovdiv, 4002, Bulgaria
  • Plovdiv, Bulgaria
  • Radnevo, 6260, Bulgaria
  • Rousse, 7003, Bulgaria
  • Sofia, 1113, Bulgaria
  • Sofia, 1431, Bulgaria
  • Sofia, 1632, Bulgaria
  • Tserova Koria, Bulgaria
  • Varna, 9001, Bulgaria
  • Varna, Bulgaria
  • Santiago, 7500710, Chile
  • Santiago, 7510186, Chile
  • Santiago, 7580307, Chile
  • Santiago, 8330838, Chile
  • Santiago, 8780000, Chile
  • Santiago, 8900085, Chile
  • Temuco, 4781151, Chile
  • Valdivia, 5090145, Chile
  • Zagreb, 10000, Croatia
  • Zagreb, 10090, Croatia
  • Zagreb, Croatia
  • Tallinn, 10614, Estonia
  • Tallinn, 10617, Estonia
  • Tartu, 50417, Estonia
  • Tartu, Estonia
  • Viljandi, 71024, Estonia
  • Helsinki, 250, Finland
  • Baja, 6500, Hungary
  • Balassagyarmat, 2660, Hungary
  • Gyõr, 9023, Hungary
  • Ahmedabad, Gujarat 380006, India
  • Mangalore, Karnataka 575018, India
  • Bangalore, India
  • Chennai, India
  • Kanpur, 208005, India
  • Pune, 411004, India

Showing the first 100 of 157 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Dec 2018, 101 months.

Results were first posted in Jan 2020, 1 year 1 month after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 101 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2010
First posted
May 25, 2010
StartActual
Jun 24, 2010
Primary completionActual
Dec 6, 2018
CompletionActual
Dec 6, 2018
Results first posted
Jan 6, 2020
Last update
Jan 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01129882
Responsible party
Sponsor
First posted
May 25, 2010
Start date
Jun 24, 2010
Primary completion
Dec 6, 2018
Completion
Dec 6, 2018
Results posted
Jan 6, 2020
Last update
Jan 6, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion